Leber's hereditary optic neuropathy (LHON) is a maternally inherited disease associated with mitochondrial DNA (mtDNA) mutations. We describe the distribution of seven different mtDNA mutations and the clinical findings in 334 LHON patients belonging to 29 families. Mutations described only in LHON at nucleotide positions 11778, 3460, and 14484 were found in 15, two, and nine families respectively. In three families none of these mutations was found. Mutations described in LHON but also in controls at nucleotide positions 15257, 13708, 4917, and 4216 were found in one, 10, three and 12 families respectively. Combinations of mtDNA mutations were found in most families. The patient population mainly consisted of 79-2% to 89'5% males except for one family with only 10 of 17 patients being males (58-9%, p-0 036). In 11 families only the 11778 mutation was found; in this group (WX) the affected males had a mean age of onset of 29-2 years and a mean visual outcome of 0-113. In seven families the 14484, 13708, and 4216 mutations were found; in this group (MA) the affected males had a mean age of onset of 22-0 years and a mean visual outcome of 0-442. In two families no mutation was found at all; in this group (YX) the affected males had a mean age of onset of 18-9 years and a mean visual outcome of 0 167. The mean age of onset in the WX group is significantly higher than in the MA group (p< 0-01) and in the YX group (p001). 
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Leber's hereditary optic neuropathy: correlations between mitochondrial genotype and visual outcome R J Oostra, P A Bolhuis, F A Wijburg, G Zorn-Ende, E M Bleeker-Wagemakers Abstract Leber's hereditary optic neuropathy (LHON) is a maternally inherited disease associated with mitochondrial DNA (mtDNA) mutations. We describe the distribution of seven different mtDNA mutations and the clinical findings in 334 LHON patients belonging to 29 families. Mutations described only in LHON at nucleotide positions 11778, 3460 , and 14484 were found in 15, two, and nine families respectively. In three families none of these mutations was found. Mutations described in LHON but also in controls at nucleotide positions 15257, 13708, 4917, and 4216 were found in one, 10, three and 12 families respectively. Combinations of mtDNA mutations were found in most families. The patient population mainly consisted of 79-2% to 89'5% males except for one family with only 10 of 17 patients being males (58-9%, p-0 036). In 11 families only the 11778 mutation was found; in this group (WX) the affected males had a mean age of onset of 29-2 years and a mean visual outcome of 0-113. In seven families the 14484, 13708, and 4216 mutations were found; in this group (MA) the affected males had a mean age of onset of years and a mean visual outcome of 0-442. In two families no mutation was found at all; in this group (YX) the affected males had a mean age of onset of 18-9 years and a mean visual outcome of 0 167. The mean age of onset in the WX group is significantly higher than in the MA group (p< 0-01) and in the YX group (p001). In most patients the age of onset is between 17 and 23 years, but it may range from less than 5 to more than 65 years.' The onset of visual loss is usually quite sudden. During a period of three to six months (the acute stage) vision rapidly deteriorates to finger counting or perception of hand movements. Visual loss may, however, be insidious and can remain subclinical for a long time. In the chronic stage a slight recovery often occurs and in about two years after the onset visual acuity stabilises between 0-05 and 0-10. The final outcome may, however, vary from little more than light perception to nearly complete visual recovery.
The interval between the onset in each eye usually amounts to a few weeks or months but it may be absent (that is, both eyes being simultaneously affected) or cover more than two years.' In some pedigrees accompanying abnormalities, especially neurological disorders, have a high incidence not only in LHON patients but also in their matrilineal sibs.'q The strictly maternal inheritance could be explained by involvement of mitochondrial DNA (mtDNA). Indeed Wallace et al9 discovered that in several LHON families a mitochondrial DNA (mtDNA) mutation was present in one of the genes coding for a protein subunit of Complex 1 of the respiratory chain (ND4) at nucleotide position 11778. Subsequent studies showed that this mutation occurred in about a half of the pedigrees examined, in patients as well as in healthy family members, but not in non-LHON related controls. [10] [11] [12] Up till now 10 other mtDNA mutations associated with LHON have been described, though some of them do not alter evolutionarily conserved amino acids and are not as specific for LHON as the 11778 mutation; most of the mutations occur in patterns of two or Table 1 Primers and restriction enzymes used in the detection of mtDNA mutations   Primers   Mutation  Forward  Reverse  Restriction  nt  Gene  np  np  enzyme   3460  ND1  3116-3135  3570-3549  BsaHI  4216  ND1  4006-4077  4670-4653  NlaIII  4917  ND2  4704-4721  5120-5103  MaeI  11778  ND4  11501-11520  11900-11881   MaeIII  13708  ND5  13570-13587  14007-13990  BstNI  14484  ND6  14389-14410  14538-14518  -15257  cytB  15101- Since we obtained the clinical data by retrospective analysis of up to 60 year old medical records we often came upon considerable gaps in the information relevant to our study, especially where it concerned anamnestic details, perimetric findings, and colour vision. Moreover, many patients were not examined at our institution so we were entirely reliant on the reports of others. We therefore concentrate this study on the following paramaters: (1) sex, (2) age of onset, and (3) final visual outcome.
Results

GENOTYPES
We found that the seven mtDNA mutations occurred in different patterns in the pedigrees tested. The 11778, 3460, and the 14484 mutations are thought to be the most important mutations pathogenetically since they alter evolutionarily highly conserved amino acids and have never been reported in non-LHON related persons, unlike the other mutations. We, therefore, differentiated the pedigrees in which only one of the LHON specific mutations occurred (coded W-, H-, and M respect- ively) from those without these mutations mutations were also present (MA*) in this (coded Y ). The 11778, 3460, and 14484 muta-family. tions did not appear simultaneously in the We found seven patients without known pedigrees tested. In these four groups, W, H-, affected matrilineal sibs in whom only the non-M-, and Y, either the 13708 (coded -A) or the specific mutation at np 4917 was present (YB) 4917 mutation (coded -B) or neither (coded -X) or none of the seven mutations at all (YX). were found. The eight resulting mutation pat-They were excluded from this study as the terns we found in the pedigrees investigated diagnosis of LHON in these patients could not are listed in table 2. be made with certainty. The remaining cohort The 4216 mutation occurred only in associ-therefore consisted of 334 patients in 29 pediation with the 13708 or the 4917 mutation. For grees. The mutation patterns in these families reasons dealt with later (see Discussion) we did are: WA (11778 and 13708), WB (11778, 4917, not differentiate the patterns for the presence and 4216), WX (only 11778), HX (only 3460), of the 4216 mutation. The 15257 mutation was MA (14484, 13708, and 4216), MA* (14484, found in only one small family, comprising a 13708, 4216, and 15257), MX (only 14484), male and his maternally related uncle. Besides YA (13708 and 4216), and YX (none). this mutation, the 14484, 13708, and 4216
Heteroplasmy (the presence of more than The mean age of onset in the male patients shows highly significant differences between the various groups (Kruskal-Wallis test: H(5, n= 273)=25-544, p<00001). These include a significantly later age of onset in the WX group compared to the MA group (p <0-00 1), the YX group (pt0 01), and the YA group (p%0 05). The means of age of onset in the WA, WB, and WX groups do not differ significantly from each other. The mean final visual acuity of the best eye in the male patients also shows highly significant differences between the various groups (Kruskal-Wallis test: H(5, n=193)=45-931, p<0-0001). These are caused by a significantly better final visual acuity in the MA group compared to the WA and WX groups (both pA0-001), to the YA group (pt0 01), and to the WB and YX groups (p ;0 05). It must be noted, however, that the final visual acuity in the MA group inclines to be binominally distributed. Of the 99 male patients, final visual acuity is equal to or more than 0 5 in 49 (49-5%) and less than 0-1 in 39 patients (38-3%), whereas only 12 patients (12-1%) have a final visual acuity between 0-1 and 0-5. Those medical records that were informative about this matter showed that a better visual outcome is very often caused by recovery after (severe) initial loss and only rarely results from a mildly elapsing acute stage. By contrast, in the WX group a final visual acuity equal to or more than 0 5 was present in only four of the 53 males (7-6%); in two of them this was because of visual recovery. The means of final visual Table 4 Mean age of onset in each group for both sexes in relation to final visual acuity Numbers between ( ) = number of affected persons in each group with known age of onset and final visual acuity. NS = not significant. acuity in the WA, WB, and WX groups did not differ significantly from each other. In all five groups mean age of onset appears to be lower in affected males with a final visual acuity equal to or more than 0 5 than in those with a final visual acuity equal to or less than 0-1, but only in the MA group is the difference slightly significant (table 4) . This weak inversely proportional correlation is possibly explained by assuming some kind of mutation independent regeneration ability of the optic nerve, which is gradually lost with increasing age. This results in a lower final acuity as the disease starts later. Although the female populations appeared to be too small for statistically significant conclusions, they are comparable to the corresponding male populations with respect to the clinical results, especially in the larger groups. There is a slightly significant difference in sex ratios between the groups (XI test = 11 -98, p = 0 036). This is entirely owing to the relatively large number of female patients in the YA group (7 of 17).
The clinical findings in the WA, WB, and WX groups are comparable with those of Newman et al. 28 years, whereas the other 12 patients, without visual recovery, had a mean age of onset of years.
Heteroplasmy for both the 11778 and the 3460 mutation has been observed in LHON families.1418222931 It has been suggested that the severity of visual impairment is reflected by the degree of heteroplasmy, that is, the amount of mutant mtDNA.2 In family S067 (WX) the two affected males, both heteroplasmic for the 11778 mutation, had a visual outcome of 0-1 and 0-2 respectively. Although their visual acuities do not differ much from the group mean, being 0 113, they both experienced a slight visual recovery after severe initial loss. This is not a usual finding in patients carrying the 11778 mutation and therefore upholds the aforementioned assumption. However, in contrast to other mitochondrial diseases, heteroplasmy is quite exceptional in LHON. It is only found in isolated cases and small pedigrees with patients in not more than two generations. Of the 29 LHON pedigrees we investigated, heteroplasmy for the mutation at np 11778 was found in only two small pedigrees, S055 (WB) and S067 (WX). We also found heteroplasmy in the mothers of the two singleton patients carrying the 3460 mutation (S069 and S083 
